Valuation: Black Diamond Therapeutics, Inc.

Market Cap 113M 98.2M 92.72M 84.2M 158M 10.81B 158M 1.11B 429M 5.49B 423M 414M 17.68B P/E 2026 *
-3.18x
P/E 2027 * -2.06x
Enterprise Value 113M 98.2M 92.72M 84.2M 158M 10.81B 158M 1.11B 429M 5.49B 423M 414M 17.68B EV / Sales 2026 *
18x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+1.55%
1 week-1.01%
Current month-6.67%
1 month-8.84%
3 months+18.07%
6 months-7.11%
Current year-19.34%
1 week 1.91
Extreme 1.91
2.02
1 month 1.91
Extreme 1.91
2.32
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
9.99
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26
NEA Management Co. LLC
OtherCompany 0 0% -
3/20/26 Free

Director

6,105 0.0107%
3/20/26 Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%-1.01%-40.24%-43.19% 113M
-0.31%+5.79%+47.13%+99.53% 70.88B
-0.32%+0.09%+37.61%+83.40% 62.49B
+5.26%+7.86%+32.24%+30.06% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
-0.27%+6.57%+24.21%-11.64% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.69B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average +0.27%+1.47%+28.53%+188.16% 27.53B
Weighted average by Cap. -0.06%+1.48%+35.24%+153.27%

Financials

2026 *2027 *
Net sales 6.25M 5.45M 5.15M 4.67M 8.76M 600M 8.79M 61.64M 23.79M 305M 23.48M 22.96M 981M -
Net income -36.96M -32.23M -30.43M -27.64M -51.78M -3.55B -52M -365M -141M -1.8B -139M -136M -5.8B -64.65M -56.37M -53.23M -48.34M -90.56M -6.2B -90.94M -638M -246M -3.15B -243M -237M -10.15B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-09-18 $1.960 +1.55% 1,178,623
26-09-17 $1.930 -0.52% 665,492
26-09-16 $1.940 -1.52% 733,907
26-09-15 $1.970 -2.96% 301,829
26-09-14 $2.030 +2.53% 514,158
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.960USD
Average target price
10.00USD
Spread / Average Target
+410.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!